Targeting Oral Biofilms with 2-Aminoimidazole/Triazole Conjugates
Award amount
$251,837Program and phase
SBIR · Phase IAward year
2010Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- AGILE SCIENCES, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- L9UJBZEVVDM1
- Solicitation number
- PHS2010-2
- Topic code
- NIDCR
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Small Molecule Antibiotic Potentiators for Drug-Resistant Bacteria
- Development of novel anti-biofilm compounds for treating chronic wounds
- Small molecules as antibiotic potentiating agents against multi-drug resistant Gram-negative infections
- Anti-biofilm agents for the treatment of pulmonary infection in cystic fibrosis p
- Evaluation of a new class of molecules for treating MRSA infective endocarditis
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- RegendoGEL for guided pulp and dentin regeneration
- CraniaMap: Joint Solution for Auto-Segmentation and Landmarking from CBCT Scans
- Improving Caries Diagnosis with Targeted Nanoparticle-Enhanced AI-Assisted Intraoral Imaging
- Epigenetic Compounds Stimulating Dental Bone Repair
- AI-linked cytomics-on-a-chip to enable near-real time identification and management of oral lichenoid lesions in primary care
Research funding history
15 SBIR/STTR records share this UEI (2009–2016). Reported award amounts total $8,631,717. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, National Science Foundation